公开(公告)号：US20240262800A1

公开(公告)日：2024-08-08

申请号：US18363229

申请日：2023-08-01

Applicant: ROHM AND HAAS ELECTRONIC MATERIALS KOREA LTD.

Inventor： Hyun-Ju KANG ,  So-Young JUNG ,  Hyo-Nim SHIN ,  Sang-Hee CHO ,  Young-Rok LIM ,  Seung-Hyun YOON

IPC: C07D263/60 ,  C07D209/94 ,  C07D277/84 ,  C07D405/04 ,  C07D405/10 ,  C07D405/14 ,  C07D409/14 ,  C07D413/12 ,  C07D487/22 ,  C09K11/06 ,  H10K50/11 ,  H10K85/60

CPC classification number: C07D263/60 ,  C07D209/94 ,  C07D277/84 ,  C07D405/04 ,  C07D405/10 ,  C07D405/14 ,  C07D409/14 ,  C07D413/12 ,  C07D487/22 ,  C09K11/06 ,  H10K50/11 ,  H10K85/656 ,  H10K85/6572 ,  H10K85/6574 ,  C09K2211/1018

Abstract: The present disclosure relates to a plurality of host materials comprising at least one first host compound and at least one second host compound and an organic electroluminescent device comprising the same. By comprising the specific combination of the compound according to the present disclosure as host materials, an organic electroluminescent device having low driving voltage, high luminous efficiency, and long lifespan characteristics can be prepared.

公开(公告)号：US10723952B2

公开(公告)日：2020-07-28

申请号：US15517441

申请日：2015-10-06

Applicant: DIC Corporation

Inventor： Masahiro Horiguchi ,  Yutaka Kadomoto ,  Tetsuo Kusumoto

IPC: G02F1/1333 ,  C09K19/38 ,  A61K8/49 ,  C07D277/82 ,  C07C251/88 ,  C08F20/18 ,  C08G65/18 ,  C07D305/06 ,  A61K8/40 ,  C08G59/20 ,  C07C251/86 ,  C09K19/54 ,  C07C323/52 ,  C09K19/32 ,  C09K19/34 ,  C08G65/26 ,  C07D513/04 ,  C07C255/55 ,  C07D277/84 ,  C07D417/12 ,  A61Q19/00 ,  A61K8/69 ,  A61K8/46 ,  A61K8/37 ,  C07D277/50 ,  C07D303/22 ,  C07D303/48 ,  C07D277/66 ,  C07D339/06 ,  C07D409/04 ,  C07D417/04 ,  C08F20/30 ,  C09K19/04 ,  A61K47/22 ,  G02F1/13363

Abstract: The present invention provides a polymerizable compound that reduces, for example, the likelihood of crystals precipitating in a polymerizable composition including the polymerizable compound and enables the polymerizable composition to have high preservation stability and a polymerizable composition including the polymerizable compound which reduces the likelihood of inconsistencies being formed in a film-like polymer produced by polymerizing the polymerizable composition. Also provided are a polymer produced by polymerizing the polymerizable composition and an optically anisotropic body including the polymer. The present invention provides the compound represented by General Formula (I), a composition including the compound, a polymer produced by polymerizing the composition, and an optically anisotropic body including the polymer.

公开(公告)号：US20200017489A1

公开(公告)日：2020-01-16

申请号：US16521925

申请日：2019-07-25

Applicant: Ohio University

Inventor： Douglas Goetz ,  Stephen C. Bergmeier ,  Mark C. McMills ,  Crina M. Orac

IPC: C07D417/14 ,  A61K31/4166 ,  A61K31/427 ,  A61K31/428 ,  A61K31/155 ,  A61K31/4439 ,  A61K45/06 ,  C07D233/84 ,  C07D277/16 ,  C07D277/36 ,  C07D277/84 ,  C07D405/04 ,  C07D413/04 ,  C07D417/04 ,  C07D417/06

Abstract: Compounds having General Formula (I) or General Formula (II): in which R1 is chosen from C1 to C10 aliphatic or heteroaliphatic groups, optionally substituted with one or more aryl groups, substituted aryl groups, heteroaryl groups, substituted heteroaryl groups, or combination thereof, R2 is chosen from aromatic moieties, substituted aromatic moieties, heteroaromatic moieties, substituted heteroaromatic moieties, and coumarin; R3 is chosen from —H, C1 to C10 aliphatic or heteroaliphatic groups, phenyl, or substituted phenyl, wherein the aliphatic or heteroaliphatic groups are optionally substituted with one or more phenyl groups, aryl groups, heteroaryl groups, substituted heteroaryl groups, or combination thereof, and wherein the aliphatic or heteroaliphatic groups are optionally bonded to R2 to form a ring; X is S or O; and Y is S or NH, may be used in pharmaceutical compositions that modify of biological signaling processes or as reagents for biological assays.

公开(公告)号：US09216972B2

公开(公告)日：2015-12-22

申请号：US13504541

申请日：2010-10-29

Applicant: T. G. Murali Dhar ,  Hai-Yun Xiao ,  Scott Hunter Watterson ,  Soo S. Ko ,  Alaric J. Dyckman ,  Charles M. Langevine ,  Jagabandhu Das ,  Robert J. Cherney

Inventor： T. G. Murali Dhar ,  Hai-Yun Xiao ,  Scott Hunter Watterson ,  Soo S. Ko ,  Alaric J. Dyckman ,  Charles M. Langevine ,  Jagabandhu Das ,  Robert J. Cherney

IPC: C07D413/04 ,  C07D231/54 ,  C07D261/20 ,  C07D277/84 ,  C07D403/06 ,  C07D413/06 ,  C07D413/14 ,  C07D417/04 ,  C07D417/14 ,  C07D419/04 ,  C07D487/10 ,  C07D498/04

CPC classification number: C07D413/04 ,  C07D231/54 ,  C07D261/20 ,  C07D277/84 ,  C07D403/06 ,  C07D413/06 ,  C07D413/14 ,  C07D417/04 ,  C07D417/14 ,  C07D419/04 ,  C07D487/10 ,  C07D498/04

Abstract: Disclosed are compounds of Formula (I) or stereoisomers or salts thereof, wherein: X1, X2, X3, W, Q1, Q2, and G2 are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

Abstract translation: 公开了式（I）的化合物或其立体异构体或其盐，其中：X1，X2，X3，W，Q1，Q2和G2在本文中定义。 还公开了使用这种化合物作为G蛋白偶联受体S1P1的选择性激动剂的方法，以及包含这些化合物的药物组合物。 这些化合物可用于治疗，预防或减缓各种治疗领域（例如自身免疫疾病和血管疾病）中的疾病或病症的进展。

公开(公告)号：US09040713B2

公开(公告)日：2015-05-26

申请号：US13818391

申请日：2011-09-27

Applicant: Keqiang Ye

Inventor： Keqiang Ye

IPC: A61K31/428 ,  A61K31/122 ,  A61K31/4439 ,  C07C69/65 ,  C07C225/30 ,  C07C321/22 ,  C07D277/84 ,  C07D307/92 ,  C07D417/12

CPC classification number: A61K31/122 ,  A61K31/428 ,  A61K31/4439 ,  C07C69/65 ,  C07C225/30 ,  C07C321/22 ,  C07D277/84 ,  C07D307/92 ,  C07D417/12

Abstract: The disclosure relates to methods of managing blood sugar levels and compositions related thereto. In certain embodiments, the disclosure relates to methods of treating or preventing diabetes, insulin resistance, or hyperglycemia comprising administering to a subject diagnosed with, at risk of or exhibiting symptoms of diabetes, insulin resistance, or hyperglycemia a pharmaceutical composition comprising a compound comprising formula I.

Abstract translation: 本公开涉及管理血糖水平的方法和与其相关的组合物。 在某些实施方案中，本公开涉及治疗或预防糖尿病，胰岛素抵抗或高血糖症的方法，包括对被诊断患有糖尿病，胰岛素抵抗或高血糖症的风险或表现出症状的受试者施用药物组合物，所述药物组合物包含式 一世。

公开(公告)号：US20130178505A1

公开(公告)日：2013-07-11

申请号：US13807132

申请日：2011-06-28

Applicant: Michael Chorev ,  Bertal Huseyin Aktas ,  Jose A. Halperin ,  Gerhard Wagner

Inventor： Michael Chorev ,  Bertal Huseyin Aktas ,  Jose A. Halperin ,  Gerhard Wagner

IPC: C07D277/84 ,  C07D513/04 ,  C07D277/42 ,  C07D417/12 ,  C07D417/04 ,  C07D277/30

CPC classification number: C07D277/84 ,  C07D233/88 ,  C07D263/48 ,  C07D277/30 ,  C07D277/42 ,  C07D277/50 ,  C07D417/04 ,  C07D417/10 ,  C07D417/12 ,  C07D513/04

Abstract: Compositions and methods for inhibiting translation are provided. Compositions, methods and kits for treating (1) cellular proliferative disorders, (2) non-proliferative, degenerative disorders, (3) viral infections, (4) disorders associated with viral infections, and/or (5) non-proliferative metabolic disorders such as type II diabetes where inhibition of translation initiation is beneficial using the compounds disclosed herein.

Abstract translation: 提供了用于抑制翻译的组合物和方法。 用于治疗（1）细胞增殖性疾病的组合物，方法和试剂盒，（2）非增殖性，退行性疾病，（3）病毒感染，（4）与病毒感染相关的病症和/或（5）非增殖性代谢紊乱 例如II型糖尿病，其中使用本文公开的化合物对翻译起始的抑制是有益的。

公开(公告)号：US08193224B2

公开(公告)日：2012-06-05

申请号：US11576429

申请日：2005-09-30

Applicant: Masataka Ihara ,  Kiyosei Takasu ,  Khanitha Pudhom ,  Hiroshi Kitaguchi ,  Masayuki Kawakami ,  Kozo Sato

Inventor： Masataka Ihara ,  Kiyosei Takasu ,  Khanitha Pudhom ,  Hiroshi Kitaguchi ,  Masayuki Kawakami ,  Kozo Sato

IPC: A61K31/427 ,  A61K31/428 ,  C07D277/66 ,  C07D277/04 ,  C07D277/84

CPC classification number: C07D277/84 ,  A61K31/427 ,  A61K31/428 ,  A61K31/4439 ,  A61K31/4709 ,  C07D277/64 ,  C07D417/14 ,  Y02A50/409 ,  Y02A50/411 ,  Y02A50/414

Abstract: The present invention is to provide a medicinal composition for preventing or treating parasitic protozoan infections, having a high selective toxicity against parasitic protozoan infection, and a superior preventive or treating effect. A medicinal composition for preventing or treating parasitic protozoan infections comprises a compound shown by the following general formula (1) as an active ingredient (wherein R represents an alkyl group, aryl group or heterocyclic group; A and B each independently represents a 5- or 6-membered ring containing at least one hetero atom, or a condensation ring wherein 1 or more 3- to 8-membered ring is condensed thereto; Y represents S, O, Se, or —NR1— (R1 represents an alkyl group, aryl group or heterocyclic group); L1, L2, L3, L4 and L5 each independently represents a methine group; Q represents a physiologically acceptable anion; k represents an integer of 0 to 2, necessary to make the electric charge of the whole molecule 0; p and q each represents an integer of 0 to 3, wherein the sum of p and q is 1 or more, and 6 or less).

Abstract translation: 本发明提供一种用于预防或治疗对寄生原虫感染具有高选择性毒性的寄生原虫感染的药物组合物，以及优异的预防或治疗效果。 用于预防或治疗寄生原生动物感染的药物组合物包含由以下通式（1）表示的化合物作为活性成分（其中R表示烷基，芳基或杂环基; A和B各自独立地表示5-或 含有至少一个杂原子的6元环或其中1个以上3〜8元环稠合的缩合环; Y表示S，O，Se或-NR1-（R1表示烷基，芳基 基团或杂环基）; L1，L2，L3，L4和L5各自独立地表示次甲基; Q表示生理上可接受的阴离子; k表示使整个分子0的电荷所必需的0至2的整数; p和q各自表示0〜3的整数，p和q的和为1以上且6以下）。

公开(公告)号：US20120007495A1

公开(公告)日：2012-01-12

申请号：US12912628

申请日：2010-10-26

Applicant: HAMADA Yuji ,  Kwan-Hee Lee

Inventor： HAMADA Yuji ,  Kwan-Hee Lee

IPC: H01J1/62 ,  C07D277/84

CPC classification number: C09K11/06 ,  C09K2211/1007 ,  C09K2211/1011 ,  C09K2211/1029 ,  C09K2211/1037 ,  C09K2211/1051 ,  C09K2211/186 ,  C09K2211/188 ,  H01L51/0077 ,  H01L51/5012

Abstract: Disclosed are an organic material including a compound represented by the following Chemical Formula 1, and an organic light emitting device including the organic material. In Chemical Formula 1, A is an oxygen (O) atom or a sulfur (S) atom, M is a divalent or trivalent metal atom, R1 is an organic group, Y is a substituted or unsubstituted condensed polycyclic aromatic group, Z1 to Z4 are independently a carbon atom or a nitrogen atom, m is an integer ranging from 1 to 4, and n is 2 or 3.

Abstract translation: 公开了包含由以下化学式1表示的化合物的有机材料和包含有机材料的有机发光器件。 在化学式1中，A是氧（O）原子或硫（S）原子，M是二价或三价金属原子，R1是有机基团，Y是取代或未取代的稠合多环芳基，Z1至Z4 独立地为碳原子或氮原子，m为1〜4的整数，n为2或3。

公开(公告)号：US07414056B2

公开(公告)日：2008-08-19

申请号：US10837778

申请日：2004-05-03

Applicant: Alaric J. Dyckman ,  Jagabandhu Das ,  Katerina Leftheris ,  Chunjian Liu ,  Robert V. Moquin ,  Stephen T. Wrobleski

Inventor： Alaric J. Dyckman ,  Jagabandhu Das ,  Katerina Leftheris ,  Chunjian Liu ,  Robert V. Moquin ,  Stephen T. Wrobleski

IPC: A61K31/501 ,  C07F9/02 ,  C07D401/12 ,  C07D271/06 ,  C07D277/84

CPC classification number: C07D231/14 ,  C07D231/12 ,  C07D231/40 ,  C07D401/12 ,  C07D413/12

Abstract: The present invention provides pyrazole derived compounds of formula (I) useful for treating p38 kinase-associated conditions, where G, X, R1, R2, R3, R4, R5, R6 and m are as defined herein. The invention further pertains to pharmaceutical compositions containing at least one compound according to the invention useful for treating p38 kinase-associated conditions, and methods of inhibiting the activity of p38 kinase in a mammal.

Abstract translation: 本发明提供了可用于治疗p38激酶相关病症的式（I）的吡唑衍生化合物，其中G，X，R 1，R 2，R 2， R 3，R 4，R 5，R 6和m如本文所定义。 本发明还涉及含有至少一种可用于治疗p38激酶相关病症的本发明化合物的药物组合物，以及抑制哺乳动物中p38激酶活性的方法。

公开(公告)号：US07022721B1

公开(公告)日：2006-04-04

申请号：US10794024

申请日：2004-03-08

Applicant: Peter C Ulrich ,  Sheng Ding Fang ,  Michael L Brines ,  Qiao-Wen Xie ,  Anthony Cerami

Inventor： Peter C Ulrich ,  Sheng Ding Fang ,  Michael L Brines ,  Qiao-Wen Xie ,  Anthony Cerami

IPC: A61K31/428 ,  C07D277/84

CPC classification number: A61K31/428 ,  A61K8/49 ,  A61Q3/02 ,  A61Q5/02 ,  A61Q5/12 ,  A61Q19/00 ,  A61Q19/08 ,  C07D277/84

Abstract: In one embodiment, the present invention relates to compounds and compositions including pharmaceutical compositions containing the compounds and associated methods that uncouple sugar-mediated coupling of proteins, lipids, nucleic acids, and other biomaterials, and any combination thereof. In another embodiment, the compositions and associated methods have utility in vivo to reduce the deleterious effects of sugar-mediated coupling processes in an organism, when the organism is exposed to the compound or composition internally, by ingestion, transdermal application, or other means. In yet another embodiment, the compositions and associated methods are useful for the ex-vivo treatment of organs, cells and tissues and external treatment of hair, nails and skin to rejuvenate them by changing deformability and increase the tissue diffusion coefficient. In a further embodiment, the present invention relates to novel compounds and pharmaceutical compositions.

Abstract translation: 在一个实施方案中，本发明涉及包含药物组合物的化合物和组合物，所述药物组合物含有化合物和解离糖介导的蛋白质，脂质，核酸和其他生物材料偶联的相关方法及其任何组合。 在另一个实施方案中，组合物和相关方法在体内通过摄入，经皮施用或其它方式在生物体内部暴露于化合物或组合物时，有效地降低糖介导的生物体中的偶联过程的有害作用。 在另一个实施方案中，组合物和相关方法可用于器官，细胞和组织的离体处理以及毛发，指甲和皮肤的外部治疗，以通过改变变形性和增加组织扩散系数使其恢复活力。 在另一个实施方案中，本发明涉及新化合物和药物组合物。